Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study by Ferrari, Serge et al.
ORIGINAL ARTICLE
Longitudinal change in hip fracture incidence after starting
risedronate or raloxifene: an observational study
Serge Ferrari • Toshitaka Nakamura •
Hiroshi Hagino • Saeko Fujiwara • Jeffrey L. Lange •
Nelson B. Watts
Received: 20 July 2010 / Accepted: 14 November 2010 / Published online: 12 January 2011
 The Japanese Society for Bone and Mineral Research and Springer 2011
Abstract This study examined patients’ risk profiles and
adherence to treatment in relation to the effect of risedr-
onate and raloxifene on hip fracture incidence. Adminis-
trative billing data were used to follow two cohorts of
women aged 65 and older after starting therapy with
either risedronate (n = 86,735) or raloxifene (n =
37,726). The fracture risk profile was described using a
6-month history period before starting therapy. Effec-
tiveness of each therapy was evaluated by comparing the
incidence of hip fractures during the first 3 months with
the subsequent 12 months among women adherent
(medication possession ratio [80%) compared with those
non-adherent to treatment. At the start of therapy, the
raloxifene cohort was younger than the risedronate cohort
(median age 73 vs. 76 years) and had fewer prior frac-
tures (p \ 0.01 for both). In the first 3 months of therapy,
hip fracture incidence was lower in the raloxifene group
(0.51 per 100 person-years) compared with the risedronate
group (0.94 per 100 person-years). In the subsequent
12 months, the incidence of hip fractures decreased
among patients adherent to the risedronate regimen
[relative risk (RR) 0.70, 95% CI 0.59–0.84, p \ 0.01] and
did not change significantly among patients adherent to
the raloxifene regimen (RR 1.02, 95% CI 0.73–1.44). In
poorly adherent patients, neither drug decreased hip
fracture risk. Risedronate treatment in adherent patients
rapidly decreased the risk of hip fractures, whereas
raloxifene treatment did not.
Keywords Bisphosphonate  Hip fracture  Osteoporosis 
Raloxifene  Risedronate
Introduction
Randomized controlled clinical trials are the gold
standard for measuring the efficacy of a therapy. All
osteoporosis drugs approved to treat postmenopausal
osteoporosis have demonstrated reduction of vertebral
fractures in placebo-controlled clinical trials. Observations
from non-comparative trials suggest that some drugs may
reduce the incidence of vertebral fractures more
efficiently than others [1–3]. Moreover, evidence for a
reduction of hip fractures exists for certain drugs,
including risedronate, alendronate, and zoledronate, but
not with ibandronate and raloxifene [1, 4]. These apparent
differences may pertain to the mode of action and
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distribution of the various drugs, and/or to the clinical
characteristics of patients included in the trials. Indeed,
recent data suggest that anti-fracture efficacy of osteo-
porosis drugs may be greater in patients with a higher
10-year fracture probability [5, 6]. Adherence to therapy
is another major contributor to drug efficacy. Subjects
who maintain a medication possession ratio (MPR) of
C80% during all the observation time are usually con-
sidered adherent to treatment, and in these circumstances
a higher level of efficacy is achieved [7–15]. How drug
efficacy, baseline fracture risk, and adherence to therapy
combine to determine fracture risk reduction in clinical
practice however remains to be investigated [16].
Because health data on millions of patients on osteo-
porosis therapies in real-world clinical practice have been
collected through administrative billing, medical records,
and registries, many recent observational studies have
examined the effectiveness of osteoporosis therapies for
reducing clinical fractures [7–15, 17–30]. Some of these
studies support that the effectiveness in reducing clinical
fractures, particularly hip fractures, in actual patients
varies among drugs, in keeping with the respective clin-
ical trials [20, 26, 27, 30]. In the current observational
study using administrative billing data, we first sought to
describe and compare the fracture risk profile of patients
initiating a bisphosphonate (risedronate) and an estrogen
agonist/antagonist (raloxifene) therapy. The fracture risk
profile included factors known to affect the probability of
fracture such as demographic characteristics, co-morbidi-
ties, concomitant medication use, and history of prior
fractures. We next sought to observe the hip fracture
incidence in these patients according to their level of
adherence to therapy. For this analysis, we followed two
cohorts of women aged 65 and older after starting either
risedronate or raloxifene therapy. Within each cohort, the
baseline hip fracture incidence was defined by the
3-month period after starting therapy. To assess if therapy
resulted in a change in fracture incidence over time, the
fracture incidence during the subsequent 12 months on
treatment was compared to the baseline incidence (first
3 months on treatment) within each cohort among women
adherent to therapy as well as those who were
non-adherent. Given the observed differences in the
fracture risk profile of patients initiating a bisphosphonate
or a selective estrogen receptor modulator, we further
explored the hip fracture incidence in a subgroup of
risedronate patients whose risk profile was matched more
closely to those receiving a selective estrogen receptor
modulator and conversely how effective a selective
estrogen receptor modulator would be for reducing hip
fractures among patients with a risk profile closer to those
receiving a bisphosphonate.
Materials and methods
Data source
Computerized records of administrative billing provide a
convenient data source for studying filled prescription use
and outcomes in large populations. Records include
patient-level data concerning: (1) inpatient and outpatient
services specified by diagnosis codes of the International
Classification of Diseases, 9th revision, clinical modifica-
tion (ICD-9-CM); (2) retail and mail-order pharmacy
dispensations specified by national drug codes; and (3)
demographic information including sex, age, and eligibility
dates of health plan coverage. The data for this study, from
January 2000 through December 2008, originated from two
mutually exclusive sources: Ingenix Lab/Rx (Eden Prai-
rie, MN) and Thomson Reuters’ MarketScan (Ann Arbor,
MI). During the study period, the average number of eli-
gible enrollees was 13 million in MarketScan, representing
multiple health plans, and 12 million in Ingenix, repre-
senting a single health plan. Geographically, one half of
this population was located in the states of Michigan,
California, Florida, Ohio, Georgia, and Texas, and one half
in the other 44 states.
Study population
The study population was comprised of two cohorts—one
starting risedronate (5 or 35 mg) and one starting raloxifene
(60 mg) therapy. Study patients were entered on the date of
their initial filled prescription between July 2000 and
December 2007. Inclusion criteria were: (1) being women
ages 65 and over to provide a study population similar in
age to that of the randomized controlled trials and for which
clinical fractures are likely to be related to osteoporosis
[31]; (2) having at least 3 months of coverage in the data
source after cohort entry to provide a minimum observation
period; and (3) having no diagnosis of a malignant neo-
plasm (ICD-9-CM codes 140–208) or Paget’s disease
(731.0) within 6 months prior to and 3 months after cohort
entry to maximize the probability that patients were being
treated for either post-menopausal osteoporosis or gluco-
corticoid-induced osteoporosis. Further description of
subject identification is provided in Table 1.
Outcome
After patients were identified, each was followed to iden-
tify the first new hip fracture. ‘‘Hip fracture’’ was defined
by an inpatient diagnosis of a fracture at the hip (ICD-
9-CM code 820, 733.14). ‘‘New’’ was defined as no evi-
dence of hip fracture in the 6 months before cohort entry.
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To increase the probability of only including osteoporotic-
related fractures, we excluded likely traumatic fractures by
eliminating diagnoses of an open fracture or of a docu-
mented cause of injury from a transportation accident
(E codes E800–E848).
Risk factors
Risk factors for fracture, which may be confounding vari-
ables, include age, fracture history, glucocorticoid use, and
diagnosis of rheumatoid arthritis. Age was at the year of
cohort entry. Fracture history was any fracture diagnosis at
the hip, wrist, humerus, clavicle, pelvis, leg, or vertebrae in
the 6 months prior to cohort entry. Glucocorticoid use was
receiving 450 mg prednisone-equivalent pills within
±90 days of cohort entry—an approximation of a daily
dose of 5 mg prednisone for at least 90 days [32]. A
diagnosis of rheumatoid arthritis was any inpatient or
outpatient diagnosis (ICD-9-CM code 714.0) within
6 months before and 3 months after cohort entry. Risk
factors not available in the data source included bone
mineral density, body mass index, smoking, alcohol
consumption, and family history of fracture.
Statistical analysis
To calculate change in hip fracture incidence within each
therapy cohort, we used a method described previously
[30]. Briefly, within each cohort, fracture incidence during
the first 3 months of therapy (baseline period) was com-
pared with the fracture incidence during the subsequent
12 months among patients adherent to treatment. Fracture
incidence during the baseline period after starting an
osteoporosis therapy likely reflects the fracture risk of the
cohort independent of any drug effect (i.e., fracture
reduction does not begin immediately after the start of
therapy). For the calculation of hip fracture incidence
during the baseline period, the denominator was the sum of
observation time within a cohort during the 3 months, and
the numerator was the number of patients within a cohort
with a new hip fracture during the 3 months.
For the calculation of hip fracture incidence during the
subsequent 12 months, the denominator included all
observation time where patients maintained a MPR of at
least 80% to filled prescriptions of risedronate (5 or 35 mg)
or raloxifene (60 mg). The 80% level utilized for the MPR
has been suggested to provide a high level of therapy
Table 1 Identification of the study population
Risedronate
Number of women in data source with first use of risedronate 5 mg (daily) (NDC = 001490471) or risedronate 35 mg (weekly)
(NDC = 001490472) between July 2000 and December 2007; aged 65 years and over
202,028
Exclude women with less than 6 months of enrollment data before first use of bisphosphonate -69,475
Exclude women with less than 3 months of enrollment data after first use of bisphosphonate -7,445
Exclude women with diagnosis of Paget’s disease (ICD-9 731.0) during period 6 months before and 3 months after first use of
bisphosphonate
-193
Exclude women with malignancy diagnoses (ICD-9 140–208) during period 6 months before and 3 months after first use of
bisphosphonate
-14,762
Exclude women with any other use of another bisphosphonate form in 6 months before first use of bisphosphonate -17,025
Exclude women with any use of any raloxifene form during period 6 months before and 3 months after first use of bisphosphonate -6,393
Number of women in bisphosphonate cohort 86,735
Raloxifene
Number of women in data source with first use of raloxifene 60 mg (daily) (NDC = 000024165) between
July 2000 and December 2007; aged 65 years and over
125,139
Exclude women with less than 6 months of enrollment data before first use of raloxifene -68,314
Exclude women with less than 3 months of enrollment data after first use of raloxifene -2,616
Exclude women with diagnosis of Paget’s disease (ICD-9 731.0) during period 6 months before and 3 months after first use
of raloxifene
-30
Exclude women with malignancy diagnoses (ICD-9 140–208) during period 6 months before and 3 months after first use
of raloxifene
-5,897
Exclude women with any other use of another raloxifene form in 6 months before first use of raloxifene -4
Exclude women with any use of any bisphosphonate form during period 6 months before and 3 months after first use of
raloxifene
-10,552
Number of women in raloxifene cohort 37,726
NDC National Drug Code
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effectiveness for bisphosphonates [7–15, 21–25]. The MPR
was calculated at 3-month intervals after cohort entry.
Therefore, patients with an MPR of at least 80% at the end
of 3 months were followed into the subsequent 3-month
period. The same process was applied at the end of 6, 9,
and 12 months. The numerator was the number of patients
with a new hip fracture preceded by a MPR of at least 80%.
A simple ratio was used to compare the incidence of
fractures between the baseline and subsequent periods.
Poisson regression was used to compute the 95%
confidence intervals around the ratio.
Two additional analyses were completed to further
evaluate the primary analysis. One analysis assessed if
there was any change in the hip fracture incidence between
the first 3 months of therapy and the subsequent period of
12 months of all observation time where patients had a
MPR \80% (i.e., not adherent to treatment). A second
analysis attempted to equate the fracture risk profile of the
two cohorts by matching. A 1:1 match on year of age (ages
65–100), fracture history (yes or no), and estrogen therapy
use (yes or no) was completed so the risedronate cohort
matched the raloxifene cohort. Hence, the number of strata
matched on was 144 (36 9 2 9 2). If the raloxifene cohort
had more patients in a stratum than the risedronate cohort,
there was a reduction in the number of risedronate matches
(i.e., of the 37,726 raloxifene patients; 37,501 had a match
in the risedronate cohort). If the risedronate cohort had
more patients in a stratum than the raloxifene cohort, then a
random sample of risedronate patients was selected. The
results presented in the matched cohort reflect the average
of three random samples.
Results
Characteristics of patients starting risedronate
or raloxifene
The study population included women 65 years of age and
older who entered into a cohort on the date of their initial
prescription filling for risedronate 5 mg daily or 35 mg
weekly (n = 86,735) or raloxifene 60 mg daily
(n = 37,726) between July 2000 and December 2007. The
data source provided a record of health care utilization for
the entire 15-month study period after cohort entry for
approximately 75% of each cohort. At cohort entry, the
patients receiving risedronate were older, had more prior
fractures, had greater use of glucocorticoids, and overall
appeared to be at greater risk for hip fracture than patients
receiving raloxifene (Table 2).
Table 2 Characteristics of patients starting therapy
Characteristics Risedronate Raloxifene
Number of women in cohort 86,735 37,726
Year of cohort entry (% cohort)
2000–2002 14 43
2003–2005 69 44
2006–2007 17 13
Age at entry (cohort median) 76 73
Age 75 and over (% cohort) 53 38
Any clinical fracture in 6 months before entry (% cohort) 9 4
Glucocorticoid use within 3 months of entry (% cohort) 6 3
Rheumatoid arthritis diagnosis within 3 months of entry (% cohort) 3 2
Estrogen use within 3 months of entry (% cohort) 14 26
Documented osteoporosis diagnosis in 6 months before entry (% cohort) 40 28
Medical specialty seen closest to entry (% cohort)
Internal medicine/family practice 55 49
Obstetrics/gynecology 4 9
Other/undetermined 41 42
Estimated 10-year probability of hip fracture at cohort entry, cohort mediana 6.0 4.0
For every characteristic, there is a statistical difference (p \ 0.01) between raloxifene and risedronate cohorts based upon chi-square test for
dichotomous variables and Wilcoxon rank sum test for continuous variables
a To summarize the impact of the available risk factors, a partial FRAXTM analysis was used to obtain an estimate of the 10-year probability of
hip fracture based on age, fracture history, glucocorticoid use, and rheumatoid arthritis diagnosis, and assuming a body mass index of 25 for all
(160 cm and 64 kg) in Caucasian women from the United States [6]. Among all patients in the cohort, the median FRAX value was reported
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Incidence of hip fractures during the baseline period
During the 3 months after starting therapy in both cohorts,
the incidence of hip fractures was higher among those of
older age, prior fracture history, and glucocorticoid use,
and lower among those using estrogen therapy (Table 3).
During these 3 months, patients receiving risedronate, for
whom a higher proportion had these risk factors, had an
incidence of hip fractures of 0.94 per 100 person-years,
nearly twice as high (p \ 0.01) as the incidence among
Table 3 Hip fracture incidence in the 3 months after cohort entry by baseline characteristics
Characteristics Risedronate Raloxifene
Women Women with
fracture
Annualized incidence
per 100 women
Women Women with
fracture
Annualized incidence
per 100 women
Complete cohort 86,735 204 0.9 37,726 48 0.5
Year of entry
2000–2002 12,591 32 1.0 16,090 17 0.4
2003–2005 59,778 134 0.9 16,594 24 0.6
2006–2007 14,366 38 1.1 5,042 7 0.6
Age 65–74 years 40,830 37 0.4 23,287 13 0.2
Age 75 and over 45,905 167 1.5 14,439 35 1.0
Clinical fracture prior to entry 8,006 44 2.2 1,466 4 1.1
No clinical fracture 78,729 160 0.8 36,260 44 0.5
Glucocorticoid use 5,261 18 1.4 1,054 2 0.8
No use 81,474 186 0.9 36,672 46 0.5
Hormone therapy use 12,292 10 0.3 9,938 3 0.1
No use 74,443 194 1.0 27,788 45 0.6
Documented osteoporosis 34,764 93 1.1 10,637 21 0.8
No documentation 51,971 111 0.9 27,089 27 0.4
Medical specialty
Internal medicine 47,508 130 1.1 18,495 28 0.6
Gynecology 3,977 1 0.1 3,349 3 0.4
Other 35,250 73 0.8 15,882 17 0.4
Ten-year hip fracture probability
1.2–6.0% 45,067 29 0.3 25,698 15 0.2
6.1–34.0% 41,668 175 1.7 12,028 33 1.1
Fig. 1 Follow-up for measure
of fracture incidence
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those receiving raloxifene, which was 0.51 per 100 person-
years.
Adherence to treatment
Patients with a MPR of at least 80% were considered to be
treatment adherent and those with less than 80% MPR were
considered to be non-adherent. At the end of the first
3 months, 72% of patients in the raloxifene cohort were
adherent, while 70% of the patients were adherent in the
risedronate cohort. These numbers continued to decrease
during the subsequent 12-month period. At the end of the
15-month observation period, the percentage of patients
adherent to treatment was 48% for raloxifene and 40% for
risedronate (Fig. 1).
Incidence of hip fractures during the subsequent
12 months
In the subsequent 12 months compared to the baseline
period, the incidence of hip fractures decreased among
patients adherent to risedronate therapy (RR 0.70, 95% CI
0.59–0.84, p \ 0.01), whereas no change was seen among
patients adherent to raloxifene (RR 0.99, 95% CI
0.72–1.37). In contrast, among those patients not adhering
to therapy, hip fracture incidence remained unchanged
across the baseline period through the subsequent
12 months for both the risedronate and raloxifene cohorts
(Table 4).
Matched analysis
To investigate the contribution of differences in baseline
fracture risk between patients treated with risedronate or
raloxifene (Table 1) in relation to the effectiveness of these
drugs in reducing hip fractures, we attempted to match the
risedronate cohort to the lower risk raloxifene cohort based
on age, fracture history, and use of estrogen therapy. In this
case, the resulting matching was incomplete as differences
(p \ 0.01) in the incidence of hip fractures remained dur-
ing the baseline period (Table 5). Nevertheless, in the
raloxifene-matched risedronate cohort, the initial hip frac-
ture incidence decreased to 0.70 per 100 patient-years (from
0.94 per 100 patient-years in the overall risedronate cohort)
(Table 4). In this relatively lower risk group, the incidence of
hip fracture in the subsequent 12 months was still signifi-
cantly reduced with risedronate therapy (Table 5).
Discussion
In this large, observational study of women aged 65 years
and older initiating either risedronate or raloxifene therapy, T
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we made three inquiries: (1) Were there any differences in
the fracture risk profile at the time of initial prescription
among these women? (2) How effective was each osteo-
porosis therapy in reducing hip fractures over time
considering the adherence level? (3) What is the contri-
bution of the baseline fracture risk to the effectiveness of
these drugs in reducing hip fractures?
Consistent with prior observations [27, 33], we observed
that patients receiving risedronate had more risk factors for
fracture at the time of initial prescription than the popu-
lation of patients receiving a selective estrogen receptor
modulator. These observations suggest that physicians are
selectively prescribing osteoporosis therapies based on
their appreciation of the patients’ risk profile and/or
specialty. While these prescription patterns are likely
clinically appropriate, selective prescribing creates a
meaningful bias for any epidemiological study of drug
effects. This bias, confounded by indication, results
because the allocation of treatment is not randomized and
the indication for treatment is related to the risk of future
outcomes [34]. As a result, this bias may lead to a false
interpretation of any comparison between treatment
groups. While there is no one best way to manage this bias,
we utilized a method in this study that makes a comparison
within a population rather than between populations. A
limitation of our method, which is a comparison in the
fracture incidence during the first 3 months of therapy to
the fracture incidence during the subsequent 12 months
among patients adherent to treatment, is the presumption
that fracture reduction does not begin immediately after
therapy; consequently, the short baseline period after
starting an osteoporosis therapy likely reflects the fracture
risk of a cohort independent of any drug effect. One
observation supporting this presumption includes changes
in bone mineral density, a surrogate marker of therapeutic
effect, whose least significant change may not be reached
until at least 1 year on therapy [35]. Another supporting
observation is that fracture reductions have not been noted
earlier than 6 months after start of therapy within post hoc,
pooled analysis of clinical trials [36, 37].
Based on our method of measuring effectiveness in this
study, we observed that the patients receiving and adherent
to risedronate had a reduction over time in the incidence of
hip fractures, whereas the patients receiving and adherent
to raloxifene had no reduction in hip fracture incidence.
The strength of this observation is the consistency between
these results and the results of clinical trials [1, 4] and
another observational study [38]. Limitations of this
observation include the limited availability of information
to describe patients (e.g., no bone mineral density results),
the inclusion of fracture outcomes not verified by medical
charts, and the potential that differences in fracture risk
profile at baseline between the risedronate and raloxifene
populations may be linked to interpretation of results. In a
recent study, McCloskey et al. [5] showed that the bis-
phosphonate clodronate was effective in women identified
by the FRAX tool (World Health Organization, Centre for
Metabolic Bone Diseases, University of Sheffield, UK) to
be at high risk even in the absence of bone mineral density
information. Kanis et al. [6] showed that bazedoxifene, an
estrogen angonist/antagonist, was effective at reducing
vertebral and clinical fractures in postmenopausal women
at high risk as assessed by FRAX. Thus, the observed
differences in the present study may be partly due to the
fracture risk profile at baseline.
To control for differences in fracture risk profile at
baseline, we attempted to equate the risedronate and
raloxifene populations on fracture risk at the time of initial
prescription by matching on several major risk factors,
including age, prior fracture, and use of estrogen therapy.
However, even after matching on these risk factors, there
remained significant differences in baseline fracture risk
during the initial 3 months of therapy (i.e., matching did
not fully control for differences between populations). It
remains possible, therefore, that even modest differences in
baseline fracture risk have an impact on the effectiveness
of these therapies [6]. On the other hand, these results
suggest that treating women at lower risk with risedronate
might be more beneficial than treating them with
raloxifene.
In conclusion, for this observational study of more than
100,000 patients receiving either risedronate or raloxifene,
differences existed in the fracture risk profile of patients at
the time of initial prescription between those starting dif-
ferent osteoporosis therapies. Among these patients, we
found that adherence to risedronate therapy rapidly
decreased the risk of hip fractures, whereas raloxifene
prescribed to women at lesser fracture risk did not. Hence,
cost-effective strategies to reduce the burden of clinical
fractures should take into account both drug efficacy and
baseline fracture risk.
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